Relday - Schizophrenia affects 1% of the world's population
I am realizing, the potential market for Relday is huge. With the massive antipsychotic market, Relday has a good chance to rake in the profits for ZGNX.
Patients and physicians will prefer this product for its ease of use and once a month dosing.
The phase 1 proved that this product delivers stable pharmacokinetics, which is key in the world of schizophrenia.
Risperidone is part of a new generation of antipsychotics that patients prefer. Older ones are dysphoric, but Risperidone gives the user a sense of wellbeing.
Anxiety usually comes with the horrible disease that is schizophrenia. Relday provides much needed relief to these patients. Literally without using this product from ZGNX these people are stuck in a nightmare. Sales should be strong.
With Relday these patients don't have to worry about taking a pill each day to function. This will improve patient compliance. Schizophrenics usually have a problem with disordered thinking, with Relday that will be alleviated.
I have about 50% of my portfolio allocated to purchase ZGNX shares, but I'm thinking about selling my other positions in favor of this no-brainer - ZGNX.
As a former drug addict, I was in a rehab one time. There I met a girl who had schizophrenia. The nurses, big male nurses, struggled to control her. They gave her a depot injection of risperidone and suddenly she was just like any other girl. The voices had stopped and she was normal. That shows the value of this medication